Eli Lilly has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization (MA) for its ulcerative colitis treatment, Mirikizumab.
England's cost-effectiveness watchdog has recommended Eli Lilly’s Verzenios treatment as an option for adjuvant treatment of certain forms of breast cancer.
The pharmaceutical firm will work with the health tech company to create a digital therapeutic intended for patients dealing with a breast cancer diagnosis.
The pharmaceutical company is partnering with Yseop to install the software company’s Augmented Analyst, designed to elevate and accelerate data analysis.
The 2022 edition of the Highly Potent Active Pharmaceutical Ingredients Summit (June 28 to 30 in Boston) will take on a range of topics, including safety.
A leader from the division of Eli Lilly explains the importance of driving greater trial inclusivity, and why collaboration is vital in making progress.
The two tech-focused firms are joining forces to work on technology solutions aimed at improving patient recruitment and enrollment for various studies.
US FDA gives marketing authorization to Lilly’s oral medication for the acute treatment of migraines in adult patients, adding to its Emgality approval almost exactly a year ago.
US FDA updates Mylan’s ANDA to commercialize a generic of Lilly’s Alimta with a tentative approval, putting the company on course to enter the market in 2022.
Courts continue to rule in favor of Lilly’s lung cancer treatment patent, as the District Court for Appeals concludes generic producers like Dr Reddy’s to be potentially infringing.
Novartis will close an OTC plant in Puerto Rico by 2019 and transfer manufacturing and packaging actives to sites in the US and facilities operated by Eli Lilly and Virbac.
The US FDA has published an import alert for an Australian manufacturing site of Eli Lilly after the agency found that its Cialis pills were tainted with the active ingredient of another popular ED (erectile dysfunction) drug -- Pfizer’s Viagra.
Big pharma employees are among the brightest minds in the world, and data released yesterday on their Wikipedia use shows their interests spread beyond drug development into lighter fare.
An online quiz about drug R&D has been criticised by economists who say its developer - Eli Lilly - is misinforming the public about the cost and time it takes to develop new medicines.
A Brazilian Court in Sao Paulo has ordered Eli Lilly pay about $450m for exposing former employees of its subsidiary to hazardous substances in a manufacturing facility operated between 1977 and 2003.
The thin profit margins associated with relatively simple sterile products has led to a reluctance to invest in operations and shortages, according to an industry expert.
Lilly says another investment in its Indianapolis facility will add a second insulin cartridge-filling line and is driven by the increasing prevalence of diabetes.
in-PharmaTechnologist presents its round-up of the latest career moves within the pharmaceutical industry, including news from Eli Lilly, Roche, and Merck.
in-PharmaTechnologist presents its latest round-up of movements in the pharma sector including appointments at Sanofi, GSK, Eli Lilly and Watson Pharmaceuticals.
Outsourcing-Pharma presents five of our top audio-visual articles of 2010, including a timeline of Lilly’s outsourcing, the need for US capacity and why biomarkers are indispensible.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Discovery Laboratories, Eli Lilly and Agios Pharmaceuticals.
Imclone has closed the manufacturing facility in Branchburg, New Jersey where it produces the cancer drug Erbitux, according to reports in the US media.
The FDA has issued Eli Lilly with a warning letter detailing a significant deviation from cGMP at its API production facility in Puerto Rico, which makes ingredients used in Humalog (insulin lispro), a diabetes treatment.
in-PharmaTechnologist presents its latest round up of appointments in the pharma sector, including a new president of Eli Lilly USA and a resignation over disagreements at Caraco.
US drugmaker Eli Lilly plans to cut 5,500 jobs by 2011 as it prepares to enter what CEO John Lechleiter said will be “the most challenging period in [the] company’s history.”
Demand for Cerep’s pharmacological profiling services picked up in the second quarter and it believes this, coupled to cost savings and commencement of delayed contracts, will help it improve in the second half of 2009.
Eli Lilly is among the organisations partnering to provide training for the Rozdravnadzor, Russia’s equivalent of the FDA, which is seeking to improve its knowledge of manufacturing standards.
in-PharmaTechnologist presents its latest round up of appointments in the pharmaceutical sector, including a former mayor joining Eli Lilly and new CEOs at three companies.
In a session chaired by at BIO 2009 John Lechleiter, CEO at Eli Lilly, speakers discussed patent reform, biosimilar bills and why certain options on the table could be a "stake in the heart" of the biotech industry.
Eli Lilly and Amylin Pharmaceuticals are jointly developing an exenatide once weekly pen device, which should provide a more convenient way for diabetics to treat themselves.
The search for more convenient diabetes treatments continues, with Altea Therapeutics reaching a $46m agreement with Eli Lilly and Amylin to develop a transdermal patch administering Byetta.
Eli Lilly’s pursuit of outsourcing deals continues unabated with the pharma major entering into a cardiovascular R&D collaboration with Zydus Cadila that has been described as a “new paradigm for global alliances”.
